| Journal | Cancers |
| Study Type | Clinical Study |
| Population | Human participants |
This review examines Akt signaling inhibition as a cancer therapeutic target, which is relevant to cannabis clinicians because cannabinoids like CBD and THC have demonstrated Akt pathway modulation in preclinical cancer models. Understanding these mechanisms helps inform discussions about cannabis as adjunctive cancer care.
This is a comprehensive review examining the PI3K/Akt signaling pathway’s role in cancer progression and therapeutic resistance. The authors highlight limitations of current synthetic Akt inhibitors, including poor isoform specificity and toxicity issues, while exploring microbial-derived natural compounds as alternative inhibitors. The review synthesizes evidence showing that certain natural compounds can effectively modulate PI3K/Akt signaling and suppress cancer hallmarks including proliferation, angiogenesis, and metastasis. However, this is a review paper rather than original clinical research, so it does not provide new primary data on patient outcomes.
“While this review doesn’t mention cannabinoids specifically, it’s relevant because multiple preclinical studies have shown CBD and other cannabinoids can inhibit Akt signaling in cancer models. This mechanistic framework helps me contextualize the growing body of laboratory evidence around cannabis compounds and cancer, though we still lack robust human clinical data.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is the PI3K/Akt signaling pathway and why is it important in cancer?
- Why have current Akt inhibitors shown limited clinical success despite promising preclinical results?
- What makes microbial-derived compounds promising as Akt inhibitors?
- How does Akt contribute to cancer treatment resistance?
- What is the current clinical relevance of targeting Akt in cancer treatment?
FAQ
What is the PI3K/Akt signaling pathway and why is it important in cancer?
The PI3K/Akt pathway is a central cellular signaling system that regulates metabolism, cell survival, and proliferation. When dysregulated, this pathway becomes a key driver of tumor initiation, progression, and resistance to cancer treatments, making it a critical target for therapeutic intervention.
Why have current Akt inhibitors shown limited clinical success despite promising preclinical results?
Current Akt inhibitors have faced challenges due to inadequate isoform specificity and unfavorable toxicity profiles. These limitations have restricted their clinical effectiveness and highlight the need for more selective therapeutic approaches with better safety margins.
What makes microbial-derived compounds promising as Akt inhibitors?
Recent research demonstrates that microbial metabolites can effectively modulate PI3K/Akt signaling with potentially better selectivity than synthetic inhibitors. These natural compounds have shown ability to suppress key cancer characteristics including proliferation, angiogenesis, and metastatic potential in laboratory studies.
How does Akt contribute to cancer treatment resistance?
Akt signaling promotes cell survival pathways that help cancer cells evade programmed cell death, a primary mechanism by which many cancer treatments work. This survival advantage allows tumors to persist despite therapeutic interventions, contributing to treatment resistance and disease progression.
What is the current clinical relevance of targeting Akt in cancer treatment?
While Akt remains an attractive therapeutic target due to its central role in cancer biology, current evidence represents an early-stage signal requiring further development. The focus on natural microbial inhibitors may offer a promising avenue for developing more effective and tolerable Akt-targeted therapies.